Lifecare ASA

Report Publication Announcement • Mar 28, 2025

Lifecare ASA Annual Report 2024

Lifecare ASA Annual Report 2024

Bergen, Norway, 28 March -- Lifecare ASA (LIFE), a medical sensor company

advancing product development for the next-generation Continuous Glucose

Monitoring (CGM), has today published its 2024 Annual Report.

Lifecare ASA has today released its 2024 Annual Report, providing insights

into Lifecare's business strategy, key milestones, and next steps toward

obtaining CE certification for its glucose sensor for use in the human

market.

2024 has been a transformative year for Lifecare, marked by significant

advancements in technology, strategic development, and market readiness. The

company has made substantial progress in developing its glucose sensor,

scaling up for large-scale manufacturing, strengthening its organization, and

moving closer to commercialization.

Lifecare is entering a pivotal phase in 2025, maintaining strong momentum in

product development and preparing for commercialization. Lifecare's continuous

glucose monitoring technology continues to advance, supported by strategic

partnerships, optimized production processes, and improvements in sensor

sensitivity. Lifecare anticipates finalizing the design of the Sencell implant

in the first half of 2025, ensuring it is optimized for manufacturing. At the

same time, Lifecare is preparing for the regulatory study to support the CE

mark application for Sencell in the human market. This study is expected to

start late 2025, with the main part taking place in 2026, targeting CE

approval and market launch by 2027.

The Annual Report is published in both the European Single Electronic Format

(ESEF) and as an PDF.

Additionally, Lifecare has published its 2024 Remuneration Report in

accordance with the Norwegian Public Limited Liability Companies Act, section

6-16b (2).

The reports are available on Lifecare's website:

https://lifecare.no/investor/reports-presentations/.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's main focus is to bring the

next generation of Continuous Glucose Monitoring ("CGM") systems to market.

Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor

technology is referred to as "Sencell" and is suitable for identifying and

monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2025-03-28 07:00 CET.